olanzapine

P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University

P4, N=70, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital

P1/2, N=520, Recruiting, First Affiliated Hospital of Chongqing Medical University | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=66, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026

OLN significantly improves memory and antioxidant levels while reducing cytokine levels, although its effects on kidney function are limited. These results underscore the intricate relationship between OLN, cognitive function, and renal health.

Post-treatment, the treatment group's SDS scores decreased from 42.64 ± 6.32 to 37.06 ± 8.34 (P<0.001), and SAS scores dropped from 50.48 ± 12.94 to 43.61 ± 13.47 (P<0.001). Anxiety and depression impair immune function in lung cancer patients, while olanzapine enhances CD3, CD4, and NK cell activity and reduces psychological distress, suggesting its potential as an adjunct in cancer immunotherapy.

Although the efficacy of ziprasidone plus mood stabilizers is comparable to that of olanzapine plus mood stabilizers in the treatment of manic episodes of bipolar disorder, ziprasidone offers advantages in improving manic symptoms (YMRS scores), reducing adverse events, and enhancing neuroendocrine indicators. It may serve as a favorable alternative in clinical practice. Further high-quality, multicenter, large-sample studies are needed to confirm its efficacy and safety.

P2, N=384, Completed, Yale University | Recruiting --> Completed

P=N/A, N=3000, Recruiting, Boryung Pharmaceutical Co., Ltd

P1, N=20, Completed, University Hospital, Basel, Switzerland | Recruiting --> Completed

Molecular docking demonstrated strong binding affinities between olanzapine and these targets, with docking scores ranging from - 5.3 to - 8.8 kilocalories per mole (kcal/mol). These findings suggest that olanzapine, as an antipsychotic, may alleviate acute agitation symptoms by modulating signaling pathways associated with neuroinflammation and neuroplasticity, providing a basis for further research into its mechanism of action in neuropsychiatric disorders.

This review covers key investigational therapies developed over the past five years, with a focus on agents targeting Growth Differentiation Factor 15 (GDF-15), including ponsegromab, AV-380, and NGM120. Additional agents include ghrelin receptor agonists (e.g. anamorelin), anabolic/catabolic modulators (ACM-001), and cannabinoids (ART27.13). The evolving role of low-dose olanzapine is also discussed in the 2023 ASCO guideline update...The lack of standardized endpoints, heterogeneity of the syndrome, and absence of FDA-approved treatments remain major barriers to treatment implementation. Multimodal strategies combining pharmacological treatment with nutritional and rehabilitative support are likely to define future therapeutic success.